At almost the hallway point of the year, health care has been far and away the top performing sector. However, that doesn’t mean that volatility has left the biotech portion of the industry. Here are three stocks that dominated the action in today’s trading session.
Shares of Alexza Pharmaceuticals
If Adasuve is approved, it will face competition from injected treatments like Eli Lilly's
It’s almost shocking to witness Arena Pharmaceuticals
Investors in competitor VIVUS
I want to caution investors who are not currently invested to stay away from Arena for the time being. Although an approval is considerably more likely than I would have guessed six months ago, lorcaserin is Arena’s only late stage drug, and a rejection would be devastating.
Today was not good for Theratechnologies
Health-care investors are always looking for the next big breakthrough, and Motley Fool co-founder David Gardner recently identified a small-cap health-care company that’s poised for monster returns. To uncover this top pick today, enjoy the special free report: "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.